Table 1. Efficacy and Safety of BRAF Plus MEK Inhibitor Combination Regimens.

	Vemurafenib plus cobimetinib	Dabrafenib plus trametinib	Encorafenib plus binimetinib
Trial	coBRIM	COMBI-d, COMBI-v (pooled analysis)	COLUMBUS
Median PFS, mo	12.6	11.1	14.9
PFS, %
3 yr	23	23	29
5 yr	14	19	N/A
Median OS, mo	22.5	25.9	33.6
OS, %
3 yr	38	44	47
5 yr	31	34	N/A
Select AEs, any grade, %
Fatigue	38	35	43
Nausea	44	37	44
Diarrhea	61	36	38
Vomiting	28	31	32
Pyrexia	32	58	20
Photosensitivity reaction	35	NR	4
Rash	42	28	16
Arthralgia	39	29	28
Increased ALT	27	48	11
Increased AST	27	59	9

Note. Information from Ascierto et al. (2021); Dummer et al. (2018b); Robert et al. (2019); Schadendorf et al. (2017).